Pain Control After Arthroscopic Shoulder Surgeries

NCT ID: NCT05686395

Last Updated: 2024-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-23

Study Completion Date

2024-08-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be conducted to compare the perioperative analgesic efficacy of ultrasound - guided interscalene brachial plexus block versus combined shoulder anterior capsular block and anterior suprascapular nerve block for arthroscopic shoulder surgeries.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Operative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1 Ultrasound-guided Interscalene Block group

In this group, ultrasound-guided ISB will be done using 10 ml of bupivacaine 0.25%.

Group Type ACTIVE_COMPARATOR

Ultrasound-guided Interscalene Block group

Intervention Type PROCEDURE

ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery

Bupivacaine

Intervention Type DRUG

bupivacaine 0.25%.

group 2 Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block

, ultrasound-guided SHAC block will be done using 10 ml of bupivacaine 0.25% injected in the interfacial plane between deltoid and subscapular muscle and 10 ml of bupivacaine 0.25% injected in the pericapsular space. Ultrasound-guided SSN block will be done using 10 ml of bupivacaine 0.25% injected at sub omohyoid space.

Group Type ACTIVE_COMPARATOR

Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block

Intervention Type PROCEDURE

Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block

Bupivacaine

Intervention Type DRUG

bupivacaine 0.25%.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultrasound-guided Interscalene Block group

ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery

Intervention Type PROCEDURE

Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block

Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block

Intervention Type PROCEDURE

Bupivacaine

bupivacaine 0.25%.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 20-65 years of both sexes, with American Society of Anesthesiologists (ASA) physical status I or II admitted for arthroscopic shoulder surgery.

Exclusion Criteria

* Patient refusal.
* Uncooperative patient.
* Patient with neurological deficit.
* Patients with respiratory disorders.
* Patient with bleeding disorders.
* Infection at the block injection site.
* Patients with history of allergy to local anesthetics.
Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hosameldin Ibrahim Ibrahim Elsayed Eldib

ASSISTANT LECTURER OF ANESTHESIA AND INTENSIVE CARE AND PAIN MEDICINE

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Medicine Tanta University

Tanta, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB0010038

Identifier Type: -

Identifier Source: org_study_id